Glycogen synthase kinase-3β is activated by matrix metalloproteinase-2 mediated proteolysis in cardiomyoblasts

Cardiovascular Research

Volumn 83, Issue 4, 2009, Pages 698-706

  Kandasamy, Arulmozhi D ^a   Schulz, Richard ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Glycogen synthase kinase 3 ; H9c2 cells; Hydrogen peroxide; Matrix metalloproteinase 2; Proteolytic cleavage

Indexed keywords

GELATINASE A; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROGEN PEROXIDE; ILOMASTAT;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CARDIOMYOBLAST; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; MYOBLAST; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CALPAIN; CELL LINE; CELL SURVIVAL; DIPEPTIDES; ENZYME ACTIVATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; HYDROGEN PEROXIDE; MATRIX METALLOPROTEINASE 2; MOLECULAR SEQUENCE DATA; MYOBLASTS, CARDIAC; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEASE INHIBITORS; RATS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 68949160008     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp175     Document Type: Article

References (41)

1. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-2154.
2. Chen Y, Chen P, Hanaoka M, Droma Y, Kubo K. Enhanced levels of prostaglandin E(2) and matrix metalloproteinase-2 correlate with the severity of airflow limitation in stable COPD. Respirology 2008;13:1014-1021.
3. Newby AC, Southgate KM, Davies M. Extracellular matrix degrading metalloproteinases in the pathogenesis of arteriosclerosis. Basic Res Cardiol 1994;89(Suppl. 1):59-70.
4. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007;87: 1285-1342.
5. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007;47:211-242.
6. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002;106: 1543-1549.
7. Bergman MR, Teerlink JR, Mahimkar R, Li L, Zhu BQ, Nguyen A et al. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol 2007;292:H1847-H1860.
8. Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, Scott PG et al. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 2005;112:544-552.
9. Sung MM, Schulz CG, Wang W, Sawicki G, Bautista-Lopez NL, Schulz R. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. J Mol Cell Cardiol 2007;43:429-436.
10. Gao CQ, Sawicki G, Suarez-Pinzon WL, Csont T, Wozniak M, Ferdinandy P et al. Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc Res 2003;57:426-433.
11. Wang W, Sawicki G, Schulz R. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res 2002;53: 165-174.
12. Leon H, Baczko I, Sawicki G, Light PE, Schulz R. Inhibition of matrix metalloproteinases prevents peroxynitrite-induced contractile dysfunction in the isolated cardiac myocyte. Br J Pharmacol 2008;153:676-683.
13. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001;65:391-426.
14. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004;29:95-102.
15. Woodgett JR. Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 2004;17:150-157.
16. Gross ER, Gross GJ. Pharmacologic therapeutics for cardiac reperfusion injury. Expert Opin Emerg Drugs 2008;12:367-388.
17. Gross ER, Hsu AK, Gross GJ. Delayed cardioprotection afforded by the glycogen synthase kinase 3 inhibitor SB-216763 occurs via a KATP- and MPTP-dependent mechanism at reperfusion. Am J Physiol Heart Circ Physiol 2008;294:H1497-H1500.
18. Goni-Oliver P, Lucas JJ, Avila J, Hernandez F. N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J Biol Chem 2007; 282:22406-22413.
19. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol 2001;280:C53-C60.
20. Rosenfeld J, Capdevielle J, Guillemot JC, Ferrara P. In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis. Anal Biochem 1992;15:173-179.
21. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999;20:3551-3567.
22. Welsh GI, Patel JC, Proud CG. Peptide substrates suitable for assaying glycogen synthase kinase-3 in crude cell extracts. Anal Biochem 1997;244: 16-21.
23. Spallarossa P, Altieri P, Garibaldi S, Ghigliotti G, Barisione C, Manca V et al. Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: the role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res 2006;69:736-745.
24. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000;101:1833-1839.
25. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 2004;113:1535-1549.
26. Coker ML, Doscher MA, Thomas CV, Galis ZS, Spinale FG. Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol 1999;277:H777-H787.
27. Rouet-Benzineb P, Buhler JM, Dreyfus P, Delcourt A, Dorent R, Perennec J et al. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail 1999;1:337- 352.
28. Denis LJ, Verweij J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest New Drugs 1999;15:175- 185.
29. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A during platelet activation mediates aggregation. Nature 1997;386:616-619.
30. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999;85:906-911.
31. Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 2000;87:670-676.
32. McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000;289:1202-1206.
33. Wang GY, Bergman MR, Nguyen AP, Turcato S, Swigart PM, Rodrigo MC et al. Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res 2006;69:688-696.
34. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785-789.
35. Goode N, Hughes K, Woodgett JR, Parker PJ. Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes. J Biol Chem 1992;267:16878-16882.
36. Fang X, Yu SX, Lu Y, Bast RC Jr, Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci USA 2000;97:11960-11965.
37. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 1999;79:609-634.
38. Galvez AS, Diwan A, Odley AM, Hahn HS, Osinska H, Melendez JG et al. Cardiomyocyte degeneration with calpain deficiency reveals a critical role in protein homeostasis. Circ Res 2007;100:1071-1078.
39. Hegstad AC, Ytrehus K, Myklebust R, Jorgensen L. Reversible ultrastructural alterations in the myocytic mitochondria of isolated rat hearts induced by oxygen radicals. Ultrastruct Pathol 1997;21:253-262.
40. Belkhiri A, Richards C, Whaley M, McQueen SA, Orr FW. Increased expression of activated matrix metalloproteinase-2 by human endothelial cells after sublethal H2O2 exposure. Lab Invest 1997;77:533-539.
41. Zhang YJ, Xu YF, Li YH, Yin J, Li HL, Wang Q et al. Peroxynitrite induces alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms. FASEB J 2006;20:1431-1442.